Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes

Drug Metabolism and Drug Interactions

Volumn 14, Issue 2, 1997, Pages 55-82

  Touw, D J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytochrome P 450; Drug interaction; Drug metabolism; Genetic polymorphism; Liver

Indexed keywords

AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DILTIAZEM; DISULFIRAM; ENOXACIN; ERYTHROMYCIN; FLUOXETINE; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENOBARBITAL; RIFAMPICIN; SEX HORMONE; UNINDEXED DRUG; UNSPECIFIC MONOOXYGENASE;

AEROBIC METABOLISM; AGE; DRUG INTERACTION; DRUG METABOLISM; DRUG OXIDATION; GENDER; GENETIC POLYMORPHISM; HUMAN; LIVER METABOLISM; REVIEW;

AGING; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; HUMANS; LIVER; MALE; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC; SEX CHARACTERISTICS;

EID: 0031438775     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-459.
2. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry 1996; 57 (Suppl 8): 17-25.
3. Bertilsson L, Dahl ML, Sjøqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341: 63.
4. Schellens JHM, Van der Wart JHF, Danhof M, Van der Velde EA, Breimer DD. Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmac 1988; 26: 373-384.
5. Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 1994; 46 (Suppl 1): 409-415.
6. Guttendorf RJ, Wedlund PJ. Genetic aspects of drug disposition and therapeutics. J Clin Pharmacol 1992; 32: 107-117.
7. Dahl ML, Iselius L, Alm C, Svensson JO, Lee D, Johansson I, Ingelman-Sundberg M, Sjøqvist F. Polymorphic 2-hydroxylation of desipramine. A population and family study. Eur J Clin Pharmacol 1993; 44: 445-450.
8. Brøsen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986; 40: 543-549.
9. Mellstrøm B, Bertilsson L, Sawe J, Schulz HU, Sjøqvist F. E- and Z-10-hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxlation. Clin Pharmacol Ther 1981; 30: 189-193.
10. Dahl ML, Ekqvist B, Widen J, Bertilsson L. Disposition of the neuroleptic zuclopentixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99-102.
11. Dahl-Puustinen ML, Liden A, Alm C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81.
12. Llerena A, Alm C, Dahl M-L, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92-97.
13. Laurent-Kenesi M-A, Funck-Brentano C, Poirier J-M, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol 1993; 36: 531-538.
14. Lennard MS, Lewis RV, Brawn LA, Tucker GT, Ramsay LE, Jackson PR, Woods HF. Timolol metabolism and debrisoquine oxidation polymorphism: a population study. Br J Clin Pharmacol 1989; 27: 429-434.
15. Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518-527.
16. Balant-Gorgia AE, Balant LP, Genet Ch, Dayer P, Aeschlimann JM, Garrone G. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 1986; 31: 449-455.
17. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-295.
18. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbø E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287.
19. Brøsen K. The pharmacokinetics of the selective serotonin reuptake inhibitors. Clin Investig 1993; 71: 1002-1009.
20. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134-1141.
21. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Bijsterveldt L, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55 (Suppl): 13-17.
22. Chen ZR, Somogyi AA, Reynolds G, Bochner F. Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br J Clin Pharmacol 1991; 31: 381-390.
23. Brøsen K, Gram LF, Kragh-Sorensen P. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metaboliser of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit 1991; 13: 177-182.
24. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90-98.
25. Muller N, Brockmoller J, Toots I. Extremely long plasma half-life of amitriptyline in a woman with the cytochrome P450IID6 29/29-kilobase wild-type allele - A slowly reversible interaction with fluoxetine. Ther Drug Monit 1991; 13: 533-536.
26. Altamura A, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214.
27. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993; 341: 967-968.
28. Drake WM, Gordon GD. Heart block in a patient on propranolol and fluoxetine. Lancet 1994; 343: 425-426.
29. Zussman BD, Davie CC, Fowles SE, Kumar R, Lang U, Wargenau M, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. BPS, Brighton, 15 December 1994; Poster.
30. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62: 145-156.
31. Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. Br J Clin Pharmac 1986; 22: 49-53.
32. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 1996; 18: 60-64.
33. Schellens JHM, Van der Wart JHF, Brugman M, Breimer DD. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989; 249: 638-645.
34. Ward SA, Helsby NA, Skjelbø E, Brøsen K, Gram L, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-seggregates with the mephenytoin oxidation polymorphism. A panel study. Br J Clin Pharmacol 1991; 31: 689-692.
35. Brøsen K, Skjelbø E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993; 36: 105-108.
36. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin Pharmacol Ther 1995; 57: 662-669.
37. Ishizaki T, Sohn D-R, Kobayasbi K, Chiba K, Lee KH, Shin S-G, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and orientals. Ther Drug Monit 1994; 16: 214-215.
38. Caraco Y, Wilkinson GR, Wood AJJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A4 by omeprazole. Clin Pharmacol Ther 1996; 60: 396-404.
39. Caraco Y, Tateishi T, Wood AJJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 62-72.
40. Shader RI, Greenblatt DJ, Von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994; 14: 375-376.
41. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1550-1552.
42. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45: 191-193.
43. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55: 481-485.
44. Greenblatt DJ. Interaction of triazolam and ketoconazole. Lancet 1995; 345: 191.
45. Greenblatt DJ, Von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry 1993; 54 (Suppl): 4-11.
46. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-19.
47. Anonymous. Drug interactions predisposing to ventricular arrhythmias. WHO Drug Information, 1996; 10: 85-86.
48. Periti P, Mazzei T, Mini E, Novellli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-131.
49. Bailey DG, Spence JD, Munzo C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-269.
50. Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, et al. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther 1991; 50: 394-403.
51. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet 1995; 345: 955-956.
52. Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61: 401-409.
53. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahlenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-28.
54. Van Dijk PA, Van der Laan JW. Grapefruitsap: voedselinteracties met geneesmiddelen. Pharm Weekbl 1997; 132: 47-52.
55. Borcherding SM, Baciewicz AM, Self TH. Update on rifampin drug interactions II. Arch Intern Med 1992; 711-716.
56. Backman JT, Olkkola KT, Neuvonen PJ. Rifampicin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
57. Diaz D, Fabre I, Daujat M, Saint Aubert B, Bories P, Michel H, et al. Omeprazole is an arylhydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-747.
58. Curi-Pedrosa R, Daujat M, Pichard L, Ourlin JC, Clair P, Gervot L. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269: 384-392.
59. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, et al. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992; 2: 173-183.
60. Bachmann K, Sanyal G, Potter J, Schavione R, Loch J. In vivo evidence that theophylline is metabolized principally by CYP1A in rats. Pharmacology 1993; 47: 1-7.
61. Bertilsson L, Carillo JA, Dahl M-L, Llerena A, Alm C, Bondesson U, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
62. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3: 413-421.
63. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose related plasma-levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989; 99 (Suppl): S38-S40.
64. Touw DJ. Metabolisme van clozapine. Een analyse van de variabelen welke het metabolisme van clozapine kunnen beinvloeden. Pharm Weekbl 1995; 130: 256-262.
65. Van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994; 151: 1289-1290.
66. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year old boy. Drug Safety 1991; 6: 460-462.
67. Dequardo JR, Roberts M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996; 153: 840-841.
68. Bertschy G, Vandel S, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction: an accidental finding [letter]. Eur J Clin Pharmacol 1991; 40: 119-120.
69. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-246.
70. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, et al. Coadministration of fluvoxamine increases serum concentration of haloperidol. J Clin Psychopharmacol 1994; 14: 340-343.
71. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994; 16: 42-45.
72. Odom-White A, De Leon J. Clozapine levels and caffeine. J Clin Psychiatry 1996; 57: 175-176.
73. Sorgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors, part 2: Renal and hepatic elimination pathways and drug interactions. Am J Med 1993; 94 (Suppl 3A): 56S-69S.
74. Farrell GC, Murray M. Human cytochrome P450 isoforms. Their genetic heterogeneity and induction by omeprazole. Gastroenterology 1990; 99: 885-889.
75. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism; a clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53: 643-650.
76. Pippenger CE. Clinically significant carbamazepine drug interactions: an overview. Epilepsia 1987; 28 (Suppl): S71-S76.
77. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54: 142-149.
78. Murphy R, Swartz R, Watkins PB. Severe acetaminophen toxicity in a patient receiving isoniazid. Ann Intern Med 1990; 113: 799-800.
79. Kando JC, Yonkers KA, O'Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1-6.
80. Haris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995; 50: 222-239.
81. Touw DJ. Metabolisme van clomipramine. Pharm Weekbl 1992; 127: 1068-1074.
82. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL. Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians. Clin Pharmacol Ther 1985; 37: 512-521.
83. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: Relation to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45: 348-355.
84. Yasumori T, Nagata K, Yang SK, Chen LS, Murayama N, Yamazoe Y, et al. Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmacogenetics 1993; 3: 291-301.
85. Reilly PE, Thompson DA, Mason SR, Hooper WD. Cytochrome P450IIIA enzymes in rat liver microsomes: involvement in C3-hydroxylation of diazepam and nordazepam but not in N-dealkylation of diazepam and temazepam. Mol Pharmacol 1990; 37: 767-774.
86. Sohn D-R, Kusaka M, Ishizaki T, Shin S-G, Jang I-J, Shin J-G, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 1992; 52: 160-169.
87. Zhang Y, Reviriego J, Lou YQ, Sjøqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther 1990; 48: 496-502.
88. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Clin Pharmacokinet 1997; 32: 357-367.
89. Koymans L, Vermeulen NPE, Van Acker SABE, Te Koppele JM, Heykants JJP, Lavrijsen K, et al. A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 1992; 5: 211-219.